BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Make your choice for a definitive Christmas getaway destination! - 2Poland open to German troops to help secure Ukraine ceasefire
- 34K televisions for Extreme Film Watching Experience
- 4These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- 5Picking the Right Air Purifier for Your Home
- Sally Rooney books may be withdrawn from UK sale over Palestine Action ban, court told
- The most effective method to Oversee Unsold SUVs in the Car Business
- Invigorating Spots To Go Kayaking All over The Planet
- Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
- UN chief warns he could refer Israel to ICJ over laws targetting UNRWA
- Figure out How to Function Successfully with Your Auto Collision Legal advisor for the Best Result
- Top 15 Style Creators Changing the Business
- Mom finds out she has cancer after noticing something was off while breastfeeding
- Dark matter may be made of pieces of giant, exotic objects — and astronomers think they know how to look for them
